Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to BuyZacks Investment Research • 05/11/23
MKT Capital Comments on Aurinia's Largest Shareholder's Plans to WITHHOLD Support for the Majority of the Board at the 2023 Annual MeetingBusiness Wire • 05/11/23
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East ConferenceBusiness Wire • 05/09/23
MKT Capital Issues Statement Regarding Aurinia's Disappointing First Quarter 2023 Financial ResultsBusiness Wire • 05/05/23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational ResultsBusiness Wire • 05/04/23
ISS Recommends Aurinia Shareholders Vote Against the Company's Named Executive Officers' CompensationBusiness Wire • 05/03/23
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus NephritisBusiness Wire • 05/03/23
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General MeetingBusiness Wire • 05/02/23
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)Business Wire • 05/02/23
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual MeetingBusiness Wire • 04/28/23
Aurinia Pharmaceuticals shareholder says sale could reward investors with nearly 200% gainProactive Investors • 04/24/23
MKT Capital Issues Letter to Aurinia Shareholders Announcing its Intention to Withhold Support for Three Directors at 2023 Annual MeetingBusiness Wire • 04/24/23
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023Business Wire • 04/24/23
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark OfficeBusiness Wire • 04/11/23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA TrialBusiness Wire • 04/05/23
Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?Zacks Investment Research • 03/27/23